Duosuo Chajian Pian (多索茶碱片)多索茶碱片
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 浙江昂利康制药有限公司Chinese legal name: 浙江昂利康制药有限公司
主要成分Active Ingredients
- 多索茶碱Duosuo Chajian
药物知识说明
多索茶碱是一种在国家药监局注册认定的药品。该药品含有多索茶碱-0ed09fe4等成分。
该药品关联的活性成分包括：多索茶碱Duosuo Chajian。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：浙江昂利康制药有限公司Chinese legal name: 浙江昂利康制药有限公司。
您可以探索含有相同成分的其他药品：多索茶碱-0ed09fe4成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 多索茶碱片) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 多索茶碱Duosuo Chajian.
Manufacturers recorded for this product: 浙江昂利康制药有限公司Chinese legal name: 浙江昂利康制药有限公司.
Explore other medicines containing the same ingredient: 多索茶碱 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 多索茶碱片Recorded Chinese name: 多索茶碱片
- 剂型Dosage form: 片剂Tablets
- 规格Specification: 0.2g*10片0.2 g × 10 tablets
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 浙江昂利康制药有限公司Chinese legal name: 浙江昂利康制药有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20000011
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20000011
Manufacturer
Chinese legal name: 浙江昂利康制药有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Keep tightly closed.
Specification
0.2 g × 10 tablets
中文说明书原文Original Chinese source label
批准文号
国药准字H20000011
生产企业
浙江昂利康制药有限公司(国产)
适应症
本品用于支气管哮喘、喘息性慢性支气管炎及其他支气管痉挛引起的呼吸困难。
用法用量
口服，通常成人每次0.2～0.4g，每日2次，饭前或饭后3小时服用，重症哮喘患者应遵医嘱用药。
不良反应
1.用黄嘌呤衍生物可能引起恶心、呕吐、上腹部疼痛、头痛、失眠、易怒、心动过速、期外收缩、呼吸急促、高血糖、蛋白尿。
2.如过量使用还会出现严重心律不齐，阵发性痉挛危象，此表现为初期中毒症状，此时应暂停用药，请医生诊断，并监测血药浓度，但在上述中毒迹象和症状完全消失后仍可继续使用。
禁忌
凡对多索茶碱或黄嘌呤衍生物类药物过敏者、急性心肌梗塞患者及哺乳期妇女禁用。
注意事项
1.茶碱类药物个体差异较大，多索茶碱剂量亦要视个体病情变化选择最佳剂量和用药方法。必要时监测血药浓度。
2.患有甲亢、窦性心动过速、心律失常者，请遵医嘱用药。
3.严重心、肺、肝、肾功能异常者以及活动性胃、十二指肠溃疡患者慎用。
4.本品不得与其他黄嘌呤类药物同时服用，建议不要同时饮用含咖啡因的饮料或食品。
贮藏
密闭保存。
规格
0.2g*10片
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.